Sasha S. Rao is counsel in Sterne Kessler’s Trial & Appellate Practice Group. Sasha has been involved in various matters before federal district courts, the International Trade Commission, and the Court of Appeals for the Federal Circuit.

Sasha’s experience spans from initial fact investigation through trial in a wide range of technologies, including pharmaceuticals, materials science, chemical arts, and automotive technology. He also has experience counseling clients in intellectual property strategy, including licensing, infringement, validity, and freedom to operate opinions.

Prior to joining the firm, Sasha was a patent litigation associate at a large IP firm and a judicial law clerk for the justices of the Massachusetts Superior Court. He is also a published author on topics covering artificial intelligence, the gig economy, and the Biologics Price Competition and Innovation Act (BPCIA).

Sasha has performed pro bono work representing unaccompanied minors in deportation proceedings in federal immigration court and representing low-income clients in fair housing matters.

Sasha received his J.D. from Boston University and B.S.E. in chemical engineering from Princeton University.

  • J.D., Boston University
  • B.S.E., Chemical Engineering, Princeton University

  • District of Columbia
  • Massachusetts
  • U.S. Court of Appeals for the Federal Circuit
  • United States Patent & Trademark Office

Related Resources

From Sasha S. Rao

Press Release

March 25, 2024

Sterne Kessler Promotes Eight Attorneys to Counsel

Sterne, Kessler, Goldstein & Fox

In the News

January 25, 2024

Petition Watch: Patent Obviousness, ADA Trials, Spoofing

Law360

In the News

January 4, 2024

Victory in the courtroom: Sweegen's Victory Redefines Stevia Sweetener

Korea IT Times

Firm Announcements

January 3, 2024

Federal Circuit Affirms Sweet Win for SweeGen in Patent Invalidity Battle

Sterne, Kessler, Goldstein & Fox

In the News

January 2, 2024

Fed. Circ. Backs Calif. Decision Invalidating Sweetener IP

Law360

In the News

November 7, 2023

Fed. Circ. Judge Casts Doubt On Sweetener Enzyme Patents

Law360

In the News

March 14, 2023

Fed. Circ. Unsure Vanda's Sleep Med Hetlioz Is Patentable

Law360

In the News

January 3, 2023

Fed. Circ. Won't Bar Generic Sleep Meds Amid Vanda Appeal

Law360

In the News

December 13, 2022

Teva, Apotex Win Ax of Patents in Sleep Drug Suit

Law360

Firm Announcements

June 9, 2022

Sterne Kessler and D.C. Bar Pro Bono Center Host Sixth Annual Small Business Clinic

Sterne, Kessler, Goldstein & Fox

Firm Announcements

May 25, 2022

Sterne Kessler Team Secures Summary Judgment of Patent Invalidity on Behalf of Sweegen, Inc. in District Court

Sterne, Kessler, Goldstein & Fox

In the News

May 24, 2022

Stevia Patent Claims Fall After SweeGen Challenge

Law360

In the News

May 24, 2022

Sweegen Wins Challenges to Rival’s Artificial Sweetener Patents

Bloomberg Law

PTAB Strategies and Insights

November 18, 2020

PTAB Strategies and Insights - November 2020

Jason D. Eisenberg, Sasha S. Rao

Bylined Articles

November 18, 2020

Missing Analysis of "Problem Being Solved" Dooms PTAB Non-Analogous Art Findings and Court Orders a Redo on Remand

Sterne, Kessler, Goldstein & Fox Jason D. Eisenberg, Sasha S. Rao

In the News

June 23, 2020

Obviousness Doomed Narcan Patents After NJ Bench Trial

Law360 Jason D. Eisenberg, Sasha S. Rao

In the News

June 5, 2020

Teva Invalidates Opiant Patents In Narcan Suit

Law360 Jason D. Eisenberg, Sasha S. Rao